Kura Oncology, Inc. (KURA) NASDAQ
8.97
-0.065(-0.72%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Kura Oncology, Inc.
Address
12730 High Bluff Drive
San Diego, CA 92130
United States of America (the)
Phone
858 500 8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
192
First IPO Date
September 16, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Troy Edward Wilson | Chairman, Chief Executive Officer & President | 1.44M | 1969 |
| Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary | 745,021 | 1971 |
| Brian T. Powl | Chief Commercial Officer | 814,998 | 1974 |
| Mollie Leoni | Chief Medical Officer | 855,297 | 1978 |
| Kathleen Ford | Chief Operating Officer | 926,501 | 1947 |
| Thomas Doyle | Senior Vice President of Finance & Accounting | 0 | 1971 |
| Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Samir Vattompadam | Senior Vice President of Global Program Leadership | 0 | N/A |
| Francis J. Burrows | Chief Scientific Officer | 0 | 1962 |
| Roger Bakale | Senior Vice President of Manufacturing & Supply Chain | 0 | N/A |
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
